EAPI: Euroapi S.A. - Summary | Jitta

Euroapi S.A.

FRA:EAPI

Price
€1.37
Loss Chance
50.8%
3.56JITTA SCORE
86.03%Over Jitta Line
Jitta Ranking
286 / 502
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (39)
Recent Business Performance (46)
Financial Strength (57)
Return to Shareholders (3)
Competitive Advantage (29)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 155.18% in the last quarter (yoy)
CapExVery High
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.56
86.03%
4.50
90.73%
2.82
128.55%
Pharmaceuticals
3.28
100.00%
3.52
100.00%
0.45
100.00%
COMPANY DESCRIPTION
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.